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Van Andel Research Institute, Grand Rapids, MI, USA Oncogene (2007 Oncogene ( ) 26, 1258 Oncogene ( -1259 Oncogene ( . doi:10.1038 When Jay Van Andel decided in 1996 that he wanted to establish a scientific institute that would benefit the health and well-being of his community and the world at large, his advisors told him he was a visionary. When Van Andel decided he wanted this institute to be centered in Grand Rapids, his advisors asked whether he was joking. What Jay Van Andel appreciated, and what his advisors could not understand, was that an exceptional leader could not only establish this institute but also position it at the forefront of biomedical research, establishing a legacy that would last through the 21st century and would serve as a nucleus for further growth of life sciences in West Michigan.
Such a leader would have to be well respected within the scientific community and possess the strength, vitality and clarity of purpose needed to promote the institute and its scientific efforts. So it was no wonder that, when the Van Andel Institute (VAI) opened its doors in 2000, Jay Van Andel and his advisors had selected George F Vande Woude as the institute's founding director (Figure 1 ). Vande Woude was well known within the scientific community not only for his outstanding achievements in cancer research, but also for his pioneering efforts to establish the Advanced Bioscience Laboratories -Basic Research Program at the National Cancer Institute (NCI) in Frederick, Maryland, as well as for his leadership in the reorganization of the intramural basic science program at the NCI. Vande Woude was also well-regarded for his service on numerous scientific advisory committees such as those of the St Jude Children's Research Hospital, the Memorial Sloan-Kettering Cancer Center and the Samuel Lunenfeld Research Institute, as well as on the editorial boards of several influential journals including Oncogene.
In the years following his appointment to VAI, Vande Woude has successfully developed a strong basic and translational cancer research program that is recognized internationally for its high standards and scientific excellence. And, as Jay Van Andel predicted, the institute is now surrounded by construction sites for more than one billion dollars in new medical sciences Jokingly dubbed the 'original, constitutively active Met mutant' by conference organizers, Vande Woude has been extremely productive, publishing more than 300 articles in the past 40 years and in the process making several seminal contributions to cancer research. His lab was the first to isolate and determine the sequence of proviral long terminal repeats (LTRs), and to demonstrate the enhancer function of the LTR promoter, showing its utility as an expression vector in eukaryotic cells. These findings led to his 1980 insight that a normal cellular proto-oncogene could be activated as an oncogene. His studies of the mos oncogene led to the discovery that the normal mos product regulates vertebrate meiotic maturation and is responsible for the production of an unfertilized egg. In 1984, Vande Woude's laboratory identified the human met oncogene as a member of the tyrosine kinase growth factor receptor family that is ubiquitously expressed in mammalian tissues. They were the first to show that inappropriate Met expression occurs in human tumors and that this signaling renders cells tumorigenic and metastatic. Later, Vande Woude, together with Stuart Aaronson, discovered that the Met ligand is a hepatocyte growth factor. This connection significantly expanded the importance of this ligand-receptor pair in the mitogenic, motogenic and morphogenic behavior of epithelial cells. Vande Woude's investigations of the biochemical pathways underlying tumor growth and metastasis and his work to develop novel therapeutics for their treatment continue to this day.
The lasting themes of Vande Woude's research were reflected in the outstanding scientific presentations from 25 leading cancer scientists, many of whom kindly agreed to contribute to this special edition of Oncogene Reviews. Tony Hunter, a co-organizer with Vande Woude of the influential Oncogene meeting, has written an entertaining retrospective on the ideas that led to the creation of that meeting's popular cartoons. Tony Pawson discusses how the modular structure of proteins allows the creation of novel signaling molecules using oncogenic chimeric proteins as an example. Many of Vande Woude's exciting findings are highlighted in contributions by Morag Park, Jim Maller and Nick Duesbery as they review Met function in tumorigenesis, the biochemical regulation of cytostatic factor and mitogen-activated protein kinase activity in vascularization, respectively. Eva and George Klein, the latter of whom with Vande Woude has co-edited the longrunning series Advances in Cancer Research, have contributed an article about the role of Epstein-Barr virus in hematopoietic malignancies. Perspectives on the role of the tumor suppressor p53 in genome integrity and cell death are discussed in articles by Karen Vousden and Arnold Levine whereas Suzanne Cory and Jerry Adams together outline how the balance between the pro-survival proteins and their BH3 ligands regulates tissue homeostasis. William Muller discusses the role of PI3K signaling in breast cancer, and Bin Teh outlines the use of expression arrays to advance the diagnosis, prognosis and treatment of renal cell carcinoma. Finally, Paul Marks describes the discovery and development of SAHA as an anti-cancer agent and Michael Dean outlines strategies for targeting drug efflux transporters in cancer stem cells.
On behalf of all the contributors, we thank Vande Woude not only for his many and varied insights into cancer biology and therapeutics but also for the motivation that he has given us to continue to strive for a comprehensive understanding, and ultimately the defeat, of this dreadful disease.
